Fig. 1
From: Clinical characterization, genetic profiling, and immune infiltration of TOX in diffuse gliomas
TOX expression is upregulated in malignant gliomas. a Analysis of TOX mRNA levels (log2) in different tumours from TCGA. b Analysis of TOX mRNA levels in WHO grade II-IV gliomas from TCGA and CGGA. c TOX expression is upregulated in IDH mutant gliomas compared with the IDH wild-type gliomas from TCGA and CGGA. d Receiver operating characteristic (ROC) curves assessing the sensitivity and specificity of TOX expression as a predictor of IDH mutation in gliomas from TCGA. e TOX expression is upregulated in the MGMT promoter methylated gliomas from TCGA. f TOX expression is upregulated in 1p/19q codeletion gliomas compared with 1p/19q non-codeletion gliomas from TCGA and CGGA. g TOX expression is upregulated in 1p/19q codeletion as well as IDH mutant gliomas from TCGA and CGGA